Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study.
Minim Invasive Ther Allied Technol
; 31(7): 1058-1065, 2022 Oct.
Article
em En
| MEDLINE
| ID: mdl-35913784
ABSTRACT
INTRODUCTION:
We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood. MATERIAL ANDMETHODS:
An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb® 300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).RESULTS:
Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb® 300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb® 300 mL compared with HA 380 (IL-6 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-α 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).CONCLUSIONS:
Both the CytoSorb® and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb® 300 device was significantly more efficient achieving the bulk of the removal in the first 120 min.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemoperfusão
/
Interleucina-10
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article